Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:28 PM
Ignite Modification Date:
2025-12-24 @ 3:28 PM
NCT ID:
NCT01639092
Eligibility Criteria:
Inclusion Criteria: All of below
* Compensated liver disease (Child-Pugh class A)
* HBsAg positive at least 6 months or more
* HBeAg positive or negative
* Confirmation of resistance mutations to Lamivudine (rtM204V/I and/or rtL180M) and ETV (rtT184 or rtS202 or rtM250) at any time before screening
* Serum HBV DNA ≥ 60 IU/mL despite continued preceding oral antiviral treatment (Serum HBV DNA should be determined by the PCR assay at the local laboratory at screening for this study)
* Patient is ambulatory.
* Patient is willing and able to comply with the study drug regimen and all other study requirements.
* The patient is willing and able to provide written informed consent to participate in the study.
Exclusion Criteria: Any of below
* Patient previously received TDF for more than 1 week
* Patient had documented resistance mutations to ADV at any time before or at screening
* Patient has a history of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, such as suspicious foci on imaging studies. In patients with such findings, HCC should be ruled-out prior to randomizing the patient for the present study.
* Patient has received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study.
* Patient has concomitant other chronic viral infection (HCV or HIV)
* Patient has evidence of renal insufficiency defined as serum creatinine \> 1.5 mg/dL
* Patient has medical condition that requires concurrent use of systemic prednisolone or other immunosuppressive agent (including chemotherapeutic agent)
* Patient is currently abusing alcohol (more than 40 g/day) or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years.
* Patient is pregnant or breastfeeding or willing to be pregnant
* Patient has one or more additional known primary or secondary causes of liver disease, other than hepatitis B (e.g., alcoholism, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's Disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease, etc.).
* A history of treated malignancy (other than hepatocellular carcinoma) is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding three years.
* Clinical signs of decompensated liver disease as indicated by any one of the following:
1. serum bilirubin \> 3 mg/dL
2. prothrombin time \> 6 seconds prolonged or INR \>1.5
3. serum albumin \< 2.8 g/dL
4. History of ascites, variceal hemorrhage, or hepatic encephalopathy
5. Child-Pugh score ≥7
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
75 Years
Study:
NCT01639092
Study Brief:
Protocol Section:
NCT01639092